Use of synthetic vectors for neutralising antibody resistant delivery of replicating adenovirus DNA

Abstract

Use of synthetic vectors to deliver genomes of conditionally replicating lytic viruses combines the strengths of viral and non-viral approaches by enabling neutralising antibody resistant deployment of cancer virotherapy. Adenovirus is particularly suitable for this application since all proteins essential for replication can be expressed from the input DNA, although the presence of terminal protein (TP) covalently linked to the 5 0 termini of the input virus genomes both improves expression of transgenes encoded in the input DNA and also enhances replication. These roles of TP were distinguished in experiments where E1-deleted Ad GFP DNA bearing TP (Ad GFP DNA-TP), delivered with DOTAP, gave a two-fold greater frequency of transduction than Ad GFP DNA(without TP) in non-complementing A549 cells, while in 293 cells (which support replication of E1-deleted viruses) the presence of TP mediated a much greater differential transgene expression, commensurate with its ability to promote replication. Subsequent studies using AdDNA for virotherapy, therefore, included covalently linked TP. AdDNA-TP delivered to A549 cells using a synthetic polyplex vector was shown to be resistant to levels of neutralising antisera that completely ablated infection by wild-type adenovirus, enabling polyplex/ Ad wild type DNA-TP to mediate a powerful cytopathic effect. Similarly in vivo, direct injection of a polyplex/Ad wild type DNA-TP into A549 tumours was neutralising antibodyresistant and enabled virus replication, whereas intact virus was neutralised by the antibody and failed to infect. The delivery of adenovirus genomes-TP using synthetic vectors should provide a strategy to bypass neutralising antibodies and facilitate clinical application of replicating adenovirus for cancer virotherapy. Gene Therapy (2006) 13, 1579-1586.

Adenovirus-Derived Vectors for Prostate Cancer Gene Therapy

“…With advances in the field of nonviral gene delivery, an alternative approach became feasible (Carlisle et al, 2006). Rather than delivering intact viruses to the tumor cells, a strategy is followed in which viral genomes are delivered.…”

Adenoviral Vectors in Veterinary Vaccine Development: Potential for Further Development

“…AdV vectors are acknowledged to be highly efficacious as vaccine carriers and are capable of inducing strong antibody, CD4 + and CD8 + T cell responses [70]. While some uses of viral vectors in cancer therapy rely on the production of a cytopathic effect within the host tissue [71] in the development of vaccines designed to protect the host against a range of pathogens such replication competent vectors are not required. Research to date shows that replication defective AdV vectors can induce higher B and T cell responses than other viral vectors (e.g.…”

Viruses as anticancer drugs

“…As an alternative to changing the virus coat or to suppressing antibody responses, recent data indicate that it could be possible to 'hide' a virus so that it cannot be seen or bound by antiviral antibodies as it transits the blood-stream to gain access to the tumor cell population [37]. This can be achieved either by using virus-infected cells as carriers to transport the virus to its target cell population [33,[38][39][40] or by delivering the virus genome to target cells as non-immunogenic infectious nucleic acid [41]. Both of these approaches have the potential to circumvent phagocytic clearance mechanisms that sequester viruses in the liver and the spleen, but they must be used in conjunction with effective targeting strategies to minimize the transduction of non-target tissues.…”